Natural Products and Neuroprotection
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
(12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig. -
(12) United States Patent (10) Patent No.: US 9.421,180 B2 Zielinski Et Al
USOO9421 180B2 (12) United States Patent (10) Patent No.: US 9.421,180 B2 Zielinski et al. (45) Date of Patent: Aug. 23, 2016 (54) ANTIOXIDANT COMPOSITIONS FOR 6,203,817 B1 3/2001 Cormier et al. .............. 424/464 TREATMENT OF INFLAMMATION OR 6,323,232 B1 1 1/2001 Keet al. ............ ... 514,408 6,521,668 B2 2/2003 Anderson et al. ..... 514f679 OXIDATIVE DAMAGE 6,572,882 B1 6/2003 Vercauteren et al. ........ 424/451 6,805,873 B2 10/2004 Gaudout et al. ....... ... 424/401 (71) Applicant: Perio Sciences, LLC, Dallas, TX (US) 7,041,322 B2 5/2006 Gaudout et al. .............. 424/765 7,179,841 B2 2/2007 Zielinski et al. .. ... 514,474 (72) Inventors: Jan Zielinski, Vista, CA (US); Thomas 2003/0069302 A1 4/2003 Zielinski ........ ... 514,452 Russell Moon, Dallas, TX (US); 2004/0037860 A1 2/2004 Maillon ...... ... 424/401 Edward P. Allen, Dallas, TX (US) 2004/0091589 A1 5, 2004 Roy et al. ... 426,265 s s 2004/0224004 A1 1 1/2004 Zielinski ..... ... 424/442 2005/0032882 A1 2/2005 Chen ............................. 514,456 (73) Assignee: Perio Sciences, LLC, Dallas, TX (US) 2005, 0137205 A1 6, 2005 Van Breen ..... 514,252.12 2005. O154054 A1 7/2005 Zielinski et al. ............. 514,474 (*) Notice: Subject to any disclaimer, the term of this 2005/0271692 Al 12/2005 Gervasio-Nugent patent is extended or adjusted under 35 et al. ............................. 424/401 2006/0173065 A1 8/2006 BeZwada ...................... 514,419 U.S.C. 154(b) by 19 days. 2006/O193790 A1 8/2006 Doyle et al. -
Regulatory Effects of Caffeic Acid Phenethyl Ester on Neuroinflammation in Microglial Cells
Int. J. Mol. Sci. 2015, 16, 5572-5589; doi:10.3390/ijms16035572 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Article Regulatory Effects of Caffeic Acid Phenethyl Ester on Neuroinflammation in Microglial Cells Cheng-Fang Tsai 1,†, Yueh-Hsiung Kuo 1,2,†, Wei-Lan Yeh 3, Caren Yu-Ju Wu 4, Hsiao-Yun Lin 5, 4 4 4 1 5,6, Sheng-Wei Lai , Yu-Shu Liu , Ling-Hsuan Wu , Jheng-Kun Lu and Dah-Yuu Lu * 1 Department of Biotechnology, Asia University, Taichung 413, Taiwan; E-Mails: [email protected] (C.-F.T.); [email protected] (Y.-H.K.); [email protected] (J.-K.L.) 2 Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung 404, Taiwan 3 Department of Cell and Tissue Engineering, Changhua Christian Hospital, Changhua 500, Taiwan; E-Mail: [email protected] 4 Graduate Institute of Basic Medical Science, College of Medicine, China Medical University, Taichung 404, Taiwan; E-Mails: [email protected] (C.Y.-J.W.); [email protected] (S.-W.L.); [email protected] (Y.-S.L.); [email protected] (L.-H.W.) 5 Graduate Institute of Neural and Cognitive Sciences, China Medical University, Taichung 404, Taiwan; E-Mail: [email protected] 6 Department of Photonics and Communication Engineering, Asia University, Taichung 413, Taiwan † These authors contributed equally to this work. * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +886-4-2205-3366 (ext. 8206); Fax: +886-4-2207-1507. Academic Editor: Guido R. -
Namenverzeichnis. Index of Names. Index Des Auteurs
Namenverzeichnis. Index of Names. Index des Auteurs. ABDERHALDEN, E. 398, 400. ARNOLD, ,V. 200, 201, 236, 237, 241. ABELSON, P. H. 379, 383, 389, 390, 393, ARONOFF, S. 26, 59, 258, 282. 394, 395, 400, 402. ASAHINA, Y. 13, 130, 131 , 175. ADAIR, G. S. 327, 371. ASANO, J. 131, 175· ADAMS, R. 147, 149, 175. ASHBY, ''I'. C. 267, 282. ADANK, K. 189, 237, 238, 241, 242, 245. ASHWORTH, B. DE 49, 61. ADRIAN, M. M. 138, 175. ASMIS, H. 190, 2lI, 214, 215, 228, 236, AGREN, G. 383, 400. 238, 241. AHLUWALIA, V. K. 13, 21, 40, 59. Aso, K. 175. AHMED, M. 173, 178. ASTON, B. C. 161, 177. AHRENS, G. 84, 118. AusKAPS, J. 434, 446. AKABORI, S. 360, 371. AVERY, G. S., Jr. 258, 270, 273, 275, ALADASHVILI, V. A. 127, 175. 276, 282, 283. ALDAG, H. J. 434, 448. ALDER, K. 77, 8o, lI8, 154, 175. BACCARINI, P. 252, 283. ALDERWEIRELDT, F. 165. BACHLI, E. 190, 204, 207, 2I5, 225, 226, ALGAR, J. 41, 59. 228, 236, 238, 239, 241, 242, 243· ALLAN, J. 34, 59· BACHMANN, E. 312, 313, 3 18. ALLEN, D. W. 332, 338, 340, 344, 345, BADER, F. E. 191, 202, 239, 241. 347, 348, 349, 350, 35 1, 352, 368 371, BAHR, K. 18 5, 187, 189, 207, 2II, 2I5, 372. 218, 219, 220, 236, 237, 238, 246. ALLEN, F. 127, 175. 'BAKER, J. W. 281, 283. ALLEN, P. W. 420, 425, 445. II BAKER, W. 3, 16, 35, 41, 43, 44, 56, 59· ALLISON, A. C. 334, 356, 372. -
(12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO). -
Pharmacology
PHARMACOLOGY STUDY GUIDE FOR THE SPECIALTY «GENERAL MEDICINE» Minsk BSMU 2018 МИНИСТЕРСТВО ЗДРАВООХРАНЕНИЯ РЕСПУБЛИКИ БЕЛАРУСЬ БЕЛОРУССКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ КАФЕДРА ФАРМАКОЛОГИИ ФАРМАКОЛОГИЯ PHARMACOLOGY Практикум для специальности «Лечебное дело» 3-е издание, исправленное Минск БГМУ 2018 2 УДК 615(076.5)(075.8)-054.6 ББК 52.81я73 Ф24 Рекомендовано Научно-методическим советом университета в качестве практикума 20.06.2018 г., протокол № 10 А в т о р ы: проф. Н. А. Бизунок, проф. Б. В. Дубовик, доц. Б. А. Волынец, доц. А. В. Волчек Р е ц е н з е нты: д-р мед. наук, проф. А. В. Хапалюк; д-р. мед. наук, проф. А. И. Волотовский Фармакология = Pharmacology : практикум для специальности «Лечебное дело» / Ф24 Н. А. Бизунок [и др.]. – 3-е изд., испр. – Минск : БГМУ, 2018. – 152 с. ISBN 978-985-21-0103-5. Содержит методические рекомендации для подготовки к лабораторным занятиям по фармакологии и задания для самостоятельной работы студентов, обучающихся по специальности 1-79 01 01 «Лечебное дело». Первое издание вышло в 2016 году. Предназначен для студентов 3-го курса медицинского факультета иностранных учащихся, изучающих фармакологию на английском языке. УДК 615(076.5)(075.8)-054.6 ББК 52.81я73 ISBN 978-985-21-0103-5 © УО «Белорусский государственный медицинский университет», 2018 3 CONTENTS INTRODUCTION ............................................................................................................................................................. 4 GENERAL PRESCRIPTION ........................................................................................................................................... -
Analysis of the Binding and Interaction Patterns of 100 Flavonoids with the Pneumococcal Virulent Protein Pneumolysin: an in Silico Virtual Screening Approach
Available online a t www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2016, 8 (16):40-51 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4 Analysis of the binding and interaction patterns of 100 flavonoids with the Pneumococcal virulent protein pneumolysin: An in silico virtual screening approach Udhaya Lavinya B., Manisha P., Sangeetha N., Premkumar N., Asha Devi S., Gunaseelan D. and Sabina E. P.* 1School of Biosciences and Technology, VIT University, Vellore - 632014, Tamilnadu, India 2Department of Computer Science, College of Computer Science & Information Systems, JAZAN University, JAZAN-82822-6694, Kingdom of Saudi Arabia. _____________________________________________________________________________________________ ABSTRACT Pneumococcal infection is one of the major causes of morbidity and mortality among children below 2 years of age in under-developed countries. Current study involves the screening and identification of potent inhibitors of the pneumococcal virulence factor pneumolysin. About 100 flavonoids were chosen from scientific literature and docked with pnuemolysin (PDB Id.: 4QQA) using Patch Dockprogram for molecular docking. The results obtained were analysed and the docked structures visualized using LigPlus software. It was found that flavonoids amurensin, diosmin, robinin, rutin, sophoroflavonoloside, spiraeoside and icariin had hydrogen bond interactions with the receptor protein pneumolysin (4QQA). Among others, robinin had the highest score (7710) revealing that it had the best geometrical fit to the receptor molecule forming 12 hydrogen bonds ranging from 0.8-3.3 Å. Keywords : Pneumococci, pneumolysin, flavonoids, antimicrobial, virtual screening _____________________________________________________________________________________________ INTRODUCTION Streptococcus pneumoniae is a gram positive pathogenic bacterium causing opportunistic infections that may be life-threating[1]. Pneumococcus is the causative agent of pneumonia and is the most common agent causing meningitis. -
Diabetic Complications: a Natural Product Perspective
Send Orders for Reprints to [email protected] Pharmaceutical Crops, 2014, 5, (Suppl 1: M4) 39-60 39 Open Access Diabetic Complications: A Natural Product Perspective S. N. C. Sridhar, Sushma Kumari and Atish T. Paul* Laboratory of Natural Drugs, Department of Pharmacy, Birla Institute of Technology and Science (BITS Pilani), Pilani campus, Pilani-333031 (Rajasthan), India Abstract: Diabetes is a chronic disease that affects over 400 million people globally. With 5.5% increase in diabetes re- lated deaths in 2010, as compared to the 2007 and World Health Organisation's projection of diabetes as the 7th leading cause of death by 2030, has dazed the current drug discovery fraternity. The major focus of drug discovery has been to- wards the control of hyperglycemia while the severe complications arising due to it have been overlooked. Plant based natural products (pure phytochemicals or in the form of crude extracts) have been the mainstay of drug discovery program for treatment of numerous human diseases. In addition, indigenous systems of medicines like Ayurveda and Traditional Chinese Medicine (TCM) possess a rich plethora of knowledge about clinically used medicinal plants for controlling the diabetic complications. With India becoming the capital of diabetes and its associated complications, the present natural products perspective is more evident and highlights the current natural products based research that has been done for the last five years in tackling diabetic complications. Keywords: Cardiovascular disease, diabetes, diabetic complications, natural products, nephropathy, neuropathy, retinopathy. INTRODUCTION in the form of pure phytochemicals (e.g. taxol, artemisinin etc.) or crude extracts (single or combinations) for the treat- Diabetes is defined as “a chronic disease that occurs ei- ment of various diseases. -
Ep 2540295 A1
(19) TZZ Z _T (11) EP 2 540 295 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 02.01.2013 Bulletin 2013/01 A61K 31/404 (2006.01) A61P 25/00 (2006.01) A61P 25/28 (2006.01) (21) Application number: 11171532.2 (22) Date of filing: 27.06.2011 (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • Briault, Sylvain GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO 45000 ORLEANS (FR) PL PT RO RS SE SI SK SM TR • Perche, Olivier Designated Extension States: 45380 LA CHAPELLE SAINT MESMIN (FR) BA ME (74) Representative: Thomas, Dean et al (71) Applicants: Cabinet Ores • Centre national de la recherche scientifique 36 rue de St Pétersbourg 75016 Paris (FR) 75008 Paris (FR) • Centre Hospitalier Régional d’Orléans 45032 Orléans Cédex 1 (FR) (54) Compositions for the treatment of Fragile X syndrome (57) The present invention relates to a composition a fluoro-oxindole or a chloro- oxindole for use in the treat- comprising a maxi-K potassium channel opener the use ment of fragile X syndrome. in the treatment of fragile X syndrome. More specifically the present invention relates to a composition comprising EP 2 540 295 A1 Printed by Jouve, 75001 PARIS (FR) 1 EP 2 540 295 A1 2 Description ularly shyness, limited eye contact, memory problems and difficulty with facial encoding and recognition. Many [0001] The present invention relates to compositions individuals with FXS also meet the diagnostic criteria for for the alleviation of neuropsychiatric symptoms and in autism. -
Cigarette Smoke May Be an Exacerbation Factor in Nonalcoholic Fatty Liver Disease Via Modulation of the PI3K/AKT Pathway
AIMS Molecular Science, 2(4): 427-439. DOI: 10.3934/molsci.2015.4.427 Received date 21 August 2015, Accepted date 23 September 2015, Published date 21 October 2015 http://www.aimspress.com/ Review Cigarette smoke may be an exacerbation factor in nonalcoholic fatty liver disease via modulation of the PI3K/AKT pathway Mayuko Ichimura1,ѱ, Akari Minami1, Noriko Nakano1, Yasuko Kitagishi1, Toshiyuki Murai2, and Satoru Matsuda1,ѱ,* 1 Department of Food Science and Nutrition, Nara Women's University, Kita-Uoya Nishimachi, Nara 630-8506, Japan 2 Department of Microbiology and Immunology and Department of Genome Biology, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita 565-0871, Japan ѱ Author contributed equally to this work. * Correspondence: Email: [email protected]; Tel: +81 742 20 3451; Fax: +81 742 20 3451. Abstract: Nonalcoholic fatty liver disease (NAFLD) characterizes a wide spectrum of pathological abnormalities ranging from simple hepatic steatosis to nonalcoholic steato-hepatitis (NASH). NAFLD may be associated with obesity and the metabolic syndrome. Metabolic syndrome is characterized by hyperglycemia and hyperinsulinemia and also contributes to NASH-associated liver fibrosis. In addition, the presence of reactive oxygen species (ROS), produced by metabolism in normal cells, is one of the most important events in both liver injury and fibrogenesis. Smoking is one of the most common reasons that ROS are produced in a cell. Accumulating evidence indicates that deregulation of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway in hepatocytes is a key molecular event associated with metabolic dysfunction, including NAFLD. Subsequent hepatic stellate cell (HSC) activation is the central event during the diseases. -
(ESI) for Integrative Biology. This Journal Is © the Royal Society of Chemistry 2017
Electronic Supplementary Material (ESI) for Integrative Biology. This journal is © The Royal Society of Chemistry 2017 Table 1 Enriched GO terms with p-value ≤ 0.05 corresponding to the over-expressed genes upon perturbation with the lung-toxic compounds. Terms with corrected p-value less than 0.001 are shown in bold. GO:0043067 regulation of programmed GO:0010941 regulation of cell death cell death GO:0042981 regulation of apoptosis GO:0010033 response to organic sub- stance GO:0043068 positive regulation of pro- GO:0010942 positive regulation of cell grammed cell death death GO:0006357 regulation of transcription GO:0043065 positive regulation of apop- from RNA polymerase II promoter tosis GO:0010035 response to inorganic sub- GO:0043066 negative regulation of stance apoptosis GO:0043069 negative regulation of pro- GO:0060548 negative regulation of cell death grammed cell death GO:0016044 membrane organization GO:0042592 homeostatic process GO:0010629 negative regulation of gene ex- GO:0001568 blood vessel development pression GO:0051172 negative regulation of nitrogen GO:0006468 protein amino acid phosphoryla- compound metabolic process tion GO:0070482 response to oxygen levels GO:0045892 negative regulation of transcrip- tion, DNA-dependent GO:0001944 vasculature development GO:0046907 intracellular transport GO:0008202 steroid metabolic process GO:0045934 negative regulation of nucle- obase, nucleoside, nucleotide and nucleic acid metabolic process GO:0006917 induction of apoptosis GO:0016481 negative regulation of transcrip- tion GO:0016125 sterol metabolic process GO:0012502 induction of programmed cell death GO:0001666 response to hypoxia GO:0051253 negative regulation of RNA metabolic process GO:0008203 cholesterol metabolic process GO:0010551 regulation of specific transcrip- tion from RNA polymerase II promoter 1 Table 2 Enriched GO terms with p-value ≤ 0.05 corresponding to the under-expressed genes upon perturbation with the lung-toxic compounds. -
CXC195 Induces Apoptosis and Endoplastic Reticulum Stress in Human Hepatocellular Carcinoma Cells by Inhibiting the PI3K/Akt/Mtor Signaling Pathway
MOLECULAR MEDICINE REPORTS 12: 8229-8236, 2015 CXC195 induces apoptosis and endoplastic reticulum stress in human hepatocellular carcinoma cells by inhibiting the PI3K/Akt/mTOR signaling pathway XIAO-LIANG CHEN1,2*, JIAN-PING FU2*, JUN SHI3, PING WAN2, HONG CAO2 and ZHI-MOU TANG4 1Department of Surgery, School of Medicine, Nanchang University; 2Department of Hepatobiliary Surgery, Jiangxi Provincial People's Hospital; 3Department of Hepatobiliary Surgery, The First Affiliated Hospital of Nanchang University; 4Department of Oncology, Jiangxi Provincial People's Hospital, Nanchang, Jiangxi 330006, P.R. China Received December 18, 2014; Accepted September 16, 2015 DOI: 10.3892/mmr.2015.4479 Abstract. CXC195 exhibits strong protective effects against in the HepG2 cells. In addition, CXC195 inhibited the phos- neuronal apoptosis by exerting antioxidant activity. However, phorylation of phosphoinositide 3-kinase (PI3K), Akt and the pharmacological function of CXC195 in cancer remains to mammalian target of rapamycin (mTOR) in the HepG2 cells. be elucidated. The present study demonstrated that CXC195 These effects were enhanced following treatment with selected exhibited significant cytotoxic effects, and induced cell cycle inhibitors of PI3K (LY294002), Akt (SH‑6) and mTOR arrest and apoptosis in HepG2 human hepatocellular carci- (rapamycin). Furthermore, these inhibitors enhanced the noma (HCC) cell lines. Following treatment of HepG2 cells pro-apoptotic effects of CXC195 in the HepG2 cells. In conclu- with 150 µΜ CXC195 for 24 , cell viability and the apoptotic sion, the results of the present study indicated that CXC195 rate were assessed using an MTT assay and Annexin V/prop- induced apoptosis and ER stress in HepG2 cells through the idium iodide staining followed by flow cytometric analysis.